Founded by two UC Berkeley graduates, DNAlite Therapeutics has been backed by the university and its Berkeley Catalyst Fund.
US-based gastrointestinal therapy developer DNAlite Therapeutics obtained $1.5m on Wednesday in a seed round that featured University of California (UC) Berkeley.
The round was led by the Catalyst Philanthropic Fund, a vehicle backed by the UC Berkeley Foundation that aims to help commercialise technologies emerging out of the institution’s College of Chemistry.
Blue Bear Ventures, a VC firm focused on UC Berkeley-linked businesses, also took part in the round, as did biopharmaceutical company BrightGene, SOSV, SVE Capital and the Baldota…
